Article

Imaging Shows How Stress Leads to Cardiovascular Disease

Author(s):

Stress directly impacts the arteries. Imaging studies enable physicians to actually see the proof, a Boston, MA team reports.

An imaging study due to be presented at the American College of Cardiology's 65th Scientific Session & Expo in Chicago, IL links stress-related amygdala activation with arterial inflammation and eventual cardiovascular disease events.

Amorina Ishai, MD and colleagues at Harvard Medical School used Massachusetts General Hospital’s PET imaging database to access 6008 cases of patients who were screened for cancer between 2005-2008.

The study group of 293 patients, 56% of them women, was created by excluding for active cancer, prior CVD, youth, autoimmune disease, taking anti-inflammatory drugs, or patients with missing or incomplete records.

Testing for evidence of a human counterpart to a known animal stress model the team had mutually blinded teams of radiologists and cardiologists evaluate 18F-FDG PET/CT images and adjudicate any CVD events in patients who had been followed an average of 3.8 years as a group. The results were striking.

“We found that the amygdala measures predicted cardiovascular disease rather robustly” said study co-author co-director of Massachusetts General Cardiac MR PET CT Program Ahmed Tawakol, MD in a press briefing. “The study illuminates, for the first time: relationship between activation of neural tissues (those associated with fear and stress) and subsequent heart disease events”.

Amygdala activity (AA) positively correlated with arterial inflammation (R=0.50, p<0.001). Importantly, AA associated with a greater risk of CVD events.

The significance withstood Framingham Risk Score correction for age and gender (P=0.019) and FRS (P=0.019). Indeed data revealed risk of cardiovascular events to be fourteen times greater at each increment of increase in measured brain stress activity (Cox analysis: HR [95% CI]: 14.1 [4.0-15.0], p<0.001).

According to Tawakol any treatment improvement or practice changes are dependent on further research.

“Future therapies could be pharmacologic but there is also a chance that those behavioral interventions might be effective and very cheap," he said, discussing the study in a conference call with reporters.

"Interestingly enough some prior science suggests that these short term behavioral interventions actually can modulate the size and activity of the stress centers-- whether or not that in turn results in a reduction in arteriosclerotic inflammation and bone marrow activation and more importantly CVD events will need to be assessed prospectively," he noted.

Related Videos
The APAC Recap: Peripheral Artery Disease at CAPP Live 2024 with Bob Ross, PA-C | Image Credit: APAC
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
AMG0001 Advances Healing in CLTI with David G. Armstrong, DPM, PhD, and Michael S. Conte, MD | Image Credit: Canva
Malin Fromme, MD | Credit: RWTH Aachen
Pavel Strnad, MD | Credit: AASLD
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Gideon Hirschfield, FRCP, PhD | Credit: UHN Foundation
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
© 2024 MJH Life Sciences

All rights reserved.